LBO — UT MD ANDERSON CANCER CENTER
IRR: 35.0% | MOIC: 4.48x
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
35.0%
IRR
4.48x
MOIC
$1.0B
Entry EV
$2.8B
Exit EV
$519.4M
Equity Invested
Sources & Uses
S&UTotal · $1.0B| Item | Amount | % | Distribution |
|---|---|---|---|
| Senior Debt | $392.0M | 38.8% | |
| Sub Debt | $98.0M | 9.7% | |
| Equity | $519.4M | 51.5% | |
| Enterprise Value | $980.1M | 97.1% | |
| Transaction Fees | $29.4M | 2.9% | |
| Total Uses | $1.0B | 100.0% |
Interpretation
INTAt 4.48x MOIC and 35.0% IRR over 5 years, this deal exceeds the typical 20% hurdle — strong candidate.
Key drivers: Check the EBITDA bridge to identify highest-probability levers, the debt schedule for leverage trajectory, or the challenge solver to see what breaks the deal.
Returns Waterfall
WFL| Component | Value |
|---|---|
| Exit Ebitda | $268.3M |
| Exit Ev | $2.8B |
| Net Debt At Exit | $490.0M |
| Equity At Exit | $2.3B |
| Equity Invested | $519.4M |
| Total Value Created | $1.8B |
| Value From Growth | $1.8B |
| Value From Multiple | $49.0M |
| Value From Deleveraging | 0.0% |